Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient Characteristics	Cohort 1∗			Cohort 2
Patient Characteristics	R/R-BL		R/R-PBL	R/R-HGBCL with rearrangements of MYC and BCL2 and/or BCL6
Characteristic	Overall, n (%)	Evaluable, n (%)	Overall,† n (%)	Overall,† n (%)
No. of patients	13 (100)	9 (100)	2 (100)	9 (100)
Sex
Male	10 (77)	7 (78)	2 (100)	7 (78)
Female	3 (23)	2 (22)	0	2 (22)
Race
American Indian or Alaska Native	0	0	0	0
Asian	1 (8)	1 (11)	0	0
Black or African American	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0
White	12 (92)	8 (89)	2 (100)	8 (89)
Data not available				1 (11)
Ethnicity
Hispanic or Latino	3 (23)	2 (22)	2 (100)	2 (22)
Not Hispanic or Latino	10 (77)	7 (78)	0	6 (67)
Data not available				1 (11)
Age at enrollment, y
Median	35	40	47	65
Range	21-55	21-55	33-60	50-81
ECOG performance status
0-1	7 (54)	6 (67)	0	7 (78)
>1	6 (46)	3 (33)	2 (100)	2 (22)
LDH
Normal	2 (15)	2 (22)	1 (50)	2 (22)
Elevated	11 (85)	7 (78)	1 (50)	7 (78)
Data not available				0
Previous line of systemic therapy
Median	3	3	3	4
Range	1-9	1-9	2-3	2-7
Previous CAR T cells	5 (38)	4 (44)	0	4 (44)
Previous allo-SCT	2 (15)	2 (22)	0	0
Previous auto-SCT	2 (15)	1 (11)	0	1 (11)
History of CNS disease
No	11 (85)	7 (78)	2 (100)	8 (89)
Yes	2 (15)	2 (22)	0	1 (11)
HIV status at enrollment
Negative	11 (85)	7 (78)	1 (50)	9 (100)
Positive	2 (15)	2 (22)	1 (50)	0
Median HIV viral load			<30	0
Range HIV viral load	<20 to 23	<20 to 23	NA	0
Median CD4 count			312	NA
Range CD4 count	20 to >200	20 to >200	NA	NA

Patient Characteristics	Cohort 1∗			Cohort 2
Patient Characteristics	R/R-BL		R/R-PBL	R/R-HGBCL with rearrangements of MYC and BCL2 and/or BCL6
Characteristic	Overall, n (%)	Evaluable, n (%)	Overall,† n (%)	Overall,† n (%)
No. of patients	13 (100)	9 (100)	2 (100)	9 (100)
Sex
Male	10 (77)	7 (78)	2 (100)	7 (78)
Female	3 (23)	2 (22)	0	2 (22)
Race
American Indian or Alaska Native	0	0	0	0
Asian	1 (8)	1 (11)	0	0
Black or African American	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0
White	12 (92)	8 (89)	2 (100)	8 (89)
Data not available				1 (11)
Ethnicity
Hispanic or Latino	3 (23)	2 (22)	2 (100)	2 (22)
Not Hispanic or Latino	10 (77)	7 (78)	0	6 (67)
Data not available				1 (11)
Age at enrollment, y
Median	35	40	47	65
Range	21-55	21-55	33-60	50-81
ECOG performance status
0-1	7 (54)	6 (67)	0	7 (78)
>1	6 (46)	3 (33)	2 (100)	2 (22)
LDH
Normal	2 (15)	2 (22)	1 (50)	2 (22)
Elevated	11 (85)	7 (78)	1 (50)	7 (78)
Data not available				0
Previous line of systemic therapy
Median	3	3	3	4
Range	1-9	1-9	2-3	2-7
Previous CAR T cells	5 (38)	4 (44)	0	4 (44)
Previous allo-SCT	2 (15)	2 (22)	0	0
Previous auto-SCT	2 (15)	1 (11)	0	1 (11)
History of CNS disease
No	11 (85)	7 (78)	2 (100)	8 (89)
Yes	2 (15)	2 (22)	0	1 (11)
HIV status at enrollment
Negative	11 (85)	7 (78)	1 (50)	9 (100)
Positive	2 (15)	2 (22)	1 (50)	0
Median HIV viral load			<30	0
Range HIV viral load	<20 to 23	<20 to 23	NA	0
Median CD4 count			312	NA
Range CD4 count	20 to >200	20 to >200	NA	NA

allo-SCT, allogeneic SCT; auto-SCT, autologous SCT; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NA, not applicable.

No patients were accrued to the cohort 1 R/R-HGBCL with rearrangements of MYC without BCL2.

All the patients were evaluable.